肝细胞癌的免疫疗法：拉丁美洲准备好迎接黄金时代了吗？
Immunotherapy for Hepatocellular Carcinoma: Is Latin America Ready for Primetime?
作者信息
Mazzolini Guillermo D, Iracheta Alexis, Malvicini Mariana, Bayo Juan
机构信息
Gene Therapy Laboratory Instituto de Investigaciones en Medicina Traslacional Consejo Nacional de Investigaciones Científicas y Técnicas-Universidad Austral Derqui-Pilar, Buenos Aires Argentina.
Consejo Nacional de Investigaciones Científicas y Técnicas Buenos Aires Argentina.
出版信息
Clin Liver Dis (Hoboken). 2020 Sep 22;16(3):96-100. doi: 10.1002/cld.919. eCollection 2020 Sep.
Abstract
Watch a video presentation of this article.
摘要
观看本文的视频演示。
相似文献
1
Immunotherapy for Hepatocellular Carcinoma: Is Latin America Ready for Primetime?
Clin Liver Dis (Hoboken). 2020 Sep 22;16(3):96-100. doi: 10.1002/cld.919. eCollection 2020 Sep.
2
Acute-on-Chronic Liver Failure: Which Definition Is Appropriate in Latin America?
Clin Liver Dis (Hoboken). 2020 Sep 22;16(3):114-116. doi: 10.1002/cld.945. eCollection 2020 Sep.
3
Hepatitis E Virus Infection: Is It Really a Problem in Latin America?
Clin Liver Dis (Hoboken). 2020 Sep 22;16(3):108-113. doi: 10.1002/cld.931. eCollection 2020 Sep.
4
Particularities of Autoimmune Hepatitis in Latin America.
Clin Liver Dis (Hoboken). 2020 Sep 22;16(3):101-107. doi: 10.1002/cld.928. eCollection 2020 Sep.
5
Impact of Herbal and Dietary Supplements Causing Drug-Induced Liver Injury in Latin America.
Clin Liver Dis (Hoboken). 2020 Sep 22;16(3):83-86. doi: 10.1002/cld.905. eCollection 2020 Sep.
6
[Allergen extracts for immunotherapy in Latin America].
Rev Alerg Mex. 2018 Jan-Mar;65(1):25-40. doi: 10.29262/ram.v65i1.287.
7
[Immunotherapy in Latin America. From the past to the future].
Rev Alerg Mex. 2008 Jan-Feb;55(1):33-7.
8
Hepatocellular carcinoma in Latin America: Diagnosis and treatment challenges.
World J Gastroenterol. 2018 Oct 7;24(37):4224-4229. doi: 10.3748/wjg.v24.i37.4224.
9
Human rights and mental health among Latin American women in situations of state-sponsored violence. Bibliographic resources.
Psychol Women Q. 1993 Dec;17(4):525-44. doi: 10.1111/j.1471-6402.1993.tb00660.x.
10
Epidemiological update of hepatitis B, C and delta in Latin America.
Antivir Ther. 2013;18(3 Pt B):429-33. doi: 10.3851/IMP2595. Epub 2013 Jun 21.
本文引用的文献
1
Hepatocellular Carcinoma.
N Engl J Med. 2019 Apr 11;380(15):1450-1462. doi: 10.1056/NEJMra1713263.
2
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3.
3
The immunology of hepatocellular carcinoma.
Nat Immunol. 2018 Mar;19(3):222-232. doi: 10.1038/s41590-018-0044-z. Epub 2018 Jan 29.
4
Hepatocellular carcinoma.
Lancet. 2018 Mar 31;391(10127):1301-1314. doi: 10.1016/S0140-6736(18)30010-2. Epub 2018 Jan 5.
5
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
Gastroenterology. 2017 Sep;153(3):812-826. doi: 10.1053/j.gastro.2017.06.007. Epub 2017 Jun 15.
6
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
7
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
J Hepatol. 2017 Mar;66(3):545-551. doi: 10.1016/j.jhep.2016.10.029. Epub 2016 Nov 2.
8
The future of immune checkpoint therapy.
Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172.
9
The yin and yang of evasion and immune activation in HCC.
J Hepatol. 2015 Jun;62(6):1420-9. doi: 10.1016/j.jhep.2015.02.038. Epub 2015 Feb 27.
10
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
J Hepatol. 2013 Jul;59(1):81-8. doi: 10.1016/j.jhep.2013.02.022. Epub 2013 Mar 4.
Zotero 插件